FunPep Company Limited (JP:4881)

:4881

4881

FunPep Company Limited

RESEARCH TOOLSreports

FunPep Company Limited (4881) Price & Analysis

Compare

0 Followers

4881 Stock Chart & Stats

¥79.00

¥1.00(0.72%)

At close: Jan 08 4:00 PM EST

¥79.00

¥1.00(0.72%)

Day’s Range― - ―

52-Week Range¥75.00 - ¥130.00

Previous CloseN/A

Volume532.20K

Average Volume (3M)245.82K

Market Cap

¥3.90B

Enterprise Value¥1.79B

Total Cash (Recent Filing)¥2.33B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.09

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.06

Shares Outstanding44,846,700

10 Day Avg. Volume262,310

30 Day Avg. Volume245,823

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)2.13

Price to Sales (P/S)9943.96

P/FCF Ratio-2.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-34.5

Revenue Forecast (FY)¥500.00M

Bulls Say, Bears Say

Bulls Say

Zero Financial LeverageZero reported debt materially reduces short-term refinancing risk and gives management optionality to pursue non-debt financing (partnerships, licensing, equity) for R&D. For a cash-burning biotech this durable capital-structure strength lowers insolvency risk versus leveraged peers.

Prior Demonstrated Revenue Growth (2024)Revenue growth in 2024 shows the company can extract commercial or partner-derived sales, evidencing some product/market traction. That historical ability to generate revenue is a durable capability management can leverage when rebuilding scale or negotiating collaborations to fund development.

Very Lean Operating HeadcountA small workforce implies a low fixed-cost base and greater agility to reallocate resources or extend runway compared with larger biotech peers. This lean structure is a lasting operational advantage that can reduce required external capital and limit burn if projects are reprioritized.

Bears Say

Severe Revenue Collapse (2025)A ~94% YoY revenue collapse is a structural setback that erodes scale, undermines recurring cash inflows, and weakens bargaining power with partners and suppliers. Rebuilding a revenue base typically requires sustained execution and investment, prolonging dependence on external capital.

Accelerating Negative Operating Cash FlowWorsening operating cash flow shows the business is not self-funding and cash burn accelerated materially in 2025. This elevates dilution and financing risk over the medium term, forcing potentially unfavorable financing, asset sales, or rushed partnerships that can impair strategic optionality.

Widening Losses And Equity ErosionRapidly widening losses coupled with large equity erosion indicate persistent value destruction and reduced balance-sheet shock absorption. Over months this undermines investor confidence, raises cost of capital, and limits ability to self-finance R&D or absorb setbacks without significant dilution.

4881 FAQ

What was FunPep Company Limited’s price range in the past 12 months?

FunPep Company Limited lowest stock price was ¥75.00 and its highest was ¥130.00 in the past 12 months.

What is FunPep Company Limited’s market cap?

FunPep Company Limited’s market cap is ¥3.90B.

When is FunPep Company Limited’s upcoming earnings report date?

FunPep Company Limited’s upcoming earnings report date is May 18, 2026 which is in 52 days.

How were FunPep Company Limited’s earnings last quarter?

FunPep Company Limited released its earnings results on Feb 12, 2026. The company reported -¥17.06 earnings per share for the quarter, missing the consensus estimate of N/A by -¥17.06.

Is FunPep Company Limited overvalued?

According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FunPep Company Limited pay dividends?

FunPep Company Limited does not currently pay dividends.

What is FunPep Company Limited’s EPS estimate?

FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FunPep Company Limited have?

FunPep Company Limited has 44,846,700 shares outstanding.

What happened to FunPep Company Limited’s price movement after its last earnings report?

FunPep Company Limited reported an EPS of -¥17.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.97%.

Which hedge fund is a major shareholder of FunPep Company Limited?

Currently, no hedge funds are holding shares in JP:4881

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FunPep Company Limited

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.